Literature DB >> 20219149

Use of a closed set questionnaire to measure primary and secondary effects of neurofibromatosis type 2.

W J Neary1, V F Hillier, T Flute, D Stephens, R T Ramsden, D G R Evans.   

Abstract

OBJECTIVES: To identify the greatest difficulties reported by people affected by neurofibromatosis type 2, and to determine the relationship between the primary and secondary effects of the disease.
DESIGN: Postal questionnaire study.
SETTING: Questionnaire sent to subjects' home addresses. PARTICIPANTS: Eighty-seven adult patients under the care of the Manchester multidisciplinary neurofibromatosis type 2 team were invited to take part. MAIN OUTCOME MEASURE: The response rate was 62 out of 87 (71 per cent).
RESULTS: Respondents' answers emphasised that their greatest problem was deafness, which resulted in communication difficulties with social contacts, close partners, family and friends. Correlation coefficients indicated a relationship between general mood changes and hearing difficulties, social communication problems, balance difficulties and mobility problems. Self-confidence was significantly related only to social communication problems.
CONCLUSIONS: The use of a closed set neurofibromatosis type 2 questionnaire identified hearing problems and subsequent communication difficulties as the main problems faced by people with this condition.

Entities:  

Mesh:

Year:  2010        PMID: 20219149     DOI: 10.1017/S0022215110000460

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  11 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

2.  First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.

Authors:  Mojtaba Talaei-Khoei; Eric Riklin; Vanessa L Merker; Monica R Sheridan; Justin T Jordan; Scott R Plotkin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2016-11-29       Impact factor: 4.130

3.  Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.

Authors:  Matthieu Peyre; Stephane Goutagny; Sandrine Imbeaud; Alexis Bozorg-Grayeli; Michele Felce; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2011-07-28       Impact factor: 12.300

4.  A Prospective Evaluation of Swallowing and Speech in Patients with Neurofibromatosis Type 2.

Authors:  Sibi Rajendran; Joseph Antonios; Beth Solomon; H Jeffrey Kim; Tianxia Wu; James Smirniotopoulos; Gretchen Scott; Sarah Benzo; Christina Hayes; John D Heiss; Prashant Chittiboina
Journal:  J Neurol Surg B Skull Base       Date:  2019-09-18

5.  Cochlear Implantation in Vestibular Schwannoma: A Systematic Literature Review.

Authors:  Kent Tadokoro; Matthew Robert Bartindale; Nadeem El-Kouri; Dennis Moore; Christopher Britt; Matthew Kircher
Journal:  J Neurol Surg B Skull Base       Date:  2021-06-08

6.  Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT.

Authors:  Vanessa L Merker; Sarah McDannold; Eric Riklin; Mojtaba Talaei-Khoei; Monica R Sheridan; Justin T Jordan; Scott R Plotkin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2017-11-08       Impact factor: 4.130

7.  Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.

Authors:  Scott R Plotkin; Simone L Ardern-Holmes; Fred G Barker; Jaishri O Blakeley; D Gareth Evans; Rosalie E Ferner; Tessa A Hadlock; Chris Halpin
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

Review 8.  Magnetic Resonance Imaging in a Neurofibromatosis Type 2 Patient with a Novel MRI-Compatible Auditory Brainstem Implant.

Authors:  Matthew Shew; Judson Bertsch; Paul Camarata; Hinrich Staecker
Journal:  J Neurol Surg Rep       Date:  2017-01

9.  Auditory Brainstem Implantation for Adults With Neurofibromatosis 2 or Severe Inner Ear Abnormalities: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2020-03-06

10.  Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials.

Authors:  Heather L Thompson; Ann Blanton; Barbara Franklin; Vanessa L Merker; Kevin H Franck; D Bradley Welling
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.